WO2008078727A1 - Composition pharmaceutique à capacité de dissolution améliorée - Google Patents

Composition pharmaceutique à capacité de dissolution améliorée Download PDF

Info

Publication number
WO2008078727A1
WO2008078727A1 PCT/JP2007/074782 JP2007074782W WO2008078727A1 WO 2008078727 A1 WO2008078727 A1 WO 2008078727A1 JP 2007074782 W JP2007074782 W JP 2007074782W WO 2008078727 A1 WO2008078727 A1 WO 2008078727A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
improved dissolution
dissolution property
azelnidipine
olmesartan medoxomil
Prior art date
Application number
PCT/JP2007/074782
Other languages
English (en)
Japanese (ja)
Inventor
Shuichi Yada
Mitsuru Kanno
Original Assignee
Daiichi Sankyo Company, Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Company, Limited filed Critical Daiichi Sankyo Company, Limited
Priority to JP2008551105A priority Critical patent/JP5241511B2/ja
Publication of WO2008078727A1 publication Critical patent/WO2008078727A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une composition pharmaceutique à capacité de dissolution améliorée, composée d'olmesartan medoxomil et d'azelnidipine. L'invention concerne de manière spécifique une composition pharmaceutique composée (A) d'olmesartan medoxomil, (B) d'azelnidipine et (C) d'un poly(alcool de vinyle) ou d'un copolymère d'alcool vinylique.
PCT/JP2007/074782 2006-12-26 2007-12-25 Composition pharmaceutique à capacité de dissolution améliorée WO2008078727A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2008551105A JP5241511B2 (ja) 2006-12-26 2007-12-25 溶出性の改善された医薬組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006349473 2006-12-26
JP2006-349473 2006-12-26

Publications (1)

Publication Number Publication Date
WO2008078727A1 true WO2008078727A1 (fr) 2008-07-03

Family

ID=39562516

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2007/074782 WO2008078727A1 (fr) 2006-12-26 2007-12-25 Composition pharmaceutique à capacité de dissolution améliorée

Country Status (4)

Country Link
JP (1) JP5241511B2 (fr)
KR (1) KR20090094287A (fr)
TW (1) TWI414310B (fr)
WO (1) WO2008078727A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010038695A1 (fr) * 2008-09-30 2010-04-08 大洋薬品工業株式会社 Préparation moulée par compression et son procédé de production
JP2011207873A (ja) * 2010-03-10 2011-10-20 Dainippon Sumitomo Pharma Co Ltd イルベサルタンとアムロジピンまたはその塩を含有する医薬組成物
JP2014080418A (ja) * 2012-09-27 2014-05-08 Sanwa Kagaku Kenkyusho Co Ltd アナグリプチン又はその塩を含有する固形製剤

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101148884B1 (ko) * 2010-02-01 2012-05-29 동성제약주식회사 용출율이 향상된 올메사탄 메독소밀 함유 고혈압 예방 또는 치료용 조성물

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002034263A1 (fr) * 2000-10-25 2002-05-02 Takeda Chemical Industries, Ltd. Agents preventifs/remedes destines a l'hypertension portale
WO2004067003A1 (fr) * 2003-01-31 2004-08-12 Sankyo Company, Limited Medicament pour la prevention et le traitement de l'arteriosclerose et de l'hypertension
CN1762354A (zh) * 2004-10-18 2006-04-26 上海药明康德新药开发有限公司 一种含有钙阻滞剂的稳定药物组合物
WO2006123765A1 (fr) * 2005-05-20 2006-11-23 Daiichi Sankyo Company, Limited Preparation recouverte d’un film
WO2006123766A1 (fr) * 2005-05-20 2006-11-23 Daichi Sankyo Company, Limited Preparation recouverte d’un film contenant du dextrose
WO2006138421A2 (fr) * 2005-06-15 2006-12-28 Elan Pharma International Limited Formulations d'azelnidipine nanoparticulaire
WO2007001066A1 (fr) * 2005-06-27 2007-01-04 Daiichi Sankyo Company, Limited Préparation pharmaceutique contenant un antagoniste du récepteur de l'angiotensine ii et un bloqueur du canal calcique

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007001067A2 (fr) * 2005-06-27 2007-01-04 Daiichi Sankyo Company, Limited Forme posologique solide
JP5063370B2 (ja) * 2005-06-27 2012-10-31 第一三共株式会社 湿式造粒製薬の調製方法

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002034263A1 (fr) * 2000-10-25 2002-05-02 Takeda Chemical Industries, Ltd. Agents preventifs/remedes destines a l'hypertension portale
WO2004067003A1 (fr) * 2003-01-31 2004-08-12 Sankyo Company, Limited Medicament pour la prevention et le traitement de l'arteriosclerose et de l'hypertension
CN1762354A (zh) * 2004-10-18 2006-04-26 上海药明康德新药开发有限公司 一种含有钙阻滞剂的稳定药物组合物
WO2006123765A1 (fr) * 2005-05-20 2006-11-23 Daiichi Sankyo Company, Limited Preparation recouverte d’un film
WO2006123766A1 (fr) * 2005-05-20 2006-11-23 Daichi Sankyo Company, Limited Preparation recouverte d’un film contenant du dextrose
WO2006138421A2 (fr) * 2005-06-15 2006-12-28 Elan Pharma International Limited Formulations d'azelnidipine nanoparticulaire
WO2007001066A1 (fr) * 2005-06-27 2007-01-04 Daiichi Sankyo Company, Limited Préparation pharmaceutique contenant un antagoniste du récepteur de l'angiotensine ii et un bloqueur du canal calcique

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JAPAN PHARMACEUTICAL EXCIPIENTS COUNCIL: "Igakuhin Tenkabutsu Jiten", vol. 1ST ED., 1994, KABUSHIKI KAISHA YAKUJI NIPPOSHA HAKKO, pages: 124 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010038695A1 (fr) * 2008-09-30 2010-04-08 大洋薬品工業株式会社 Préparation moulée par compression et son procédé de production
JPWO2010038695A1 (ja) * 2008-09-30 2012-03-01 大洋薬品工業株式会社 圧縮成型製剤およびその製造方法
JP5694773B2 (ja) * 2008-09-30 2015-04-01 テバ製薬株式会社 圧縮成型製剤およびその製造方法
JP2011207873A (ja) * 2010-03-10 2011-10-20 Dainippon Sumitomo Pharma Co Ltd イルベサルタンとアムロジピンまたはその塩を含有する医薬組成物
JP2014055173A (ja) * 2010-03-10 2014-03-27 Dainippon Sumitomo Pharma Co Ltd イルベサルタンとアムロジピンまたはその塩を含有する医薬組成物
JP2015221826A (ja) * 2010-03-10 2015-12-10 大日本住友製薬株式会社 イルベサルタンとアムロジピンまたはその塩を含有する医薬組成物
JP2017052785A (ja) * 2010-03-10 2017-03-16 大日本住友製薬株式会社 イルベサルタンとアムロジピンまたはその塩を含有する医薬組成物
JP2018035202A (ja) * 2010-03-10 2018-03-08 大日本住友製薬株式会社 イルベサルタンとアムロジピンまたはその塩を含有する医薬組成物
JP2019069981A (ja) * 2010-03-10 2019-05-09 大日本住友製薬株式会社 イルベサルタンとアムロジピンまたはその塩を含有する医薬組成物
JP2020094064A (ja) * 2010-03-10 2020-06-18 大日本住友製薬株式会社 イルベサルタンとアムロジピンまたはその塩を含有する医薬組成物
JP2014080418A (ja) * 2012-09-27 2014-05-08 Sanwa Kagaku Kenkyusho Co Ltd アナグリプチン又はその塩を含有する固形製剤

Also Published As

Publication number Publication date
KR20090094287A (ko) 2009-09-04
TW200833359A (en) 2008-08-16
TWI414310B (zh) 2013-11-11
JPWO2008078727A1 (ja) 2010-04-30
JP5241511B2 (ja) 2013-07-17

Similar Documents

Publication Publication Date Title
WO2009057569A1 (fr) Préparation pelliculée
BRPI0716171A2 (pt) composto, composiÇço farmacÊutica e uso de um composto.
WO2008115281A3 (fr) Composés de traitement d'infections virales
WO2008037716A3 (fr) Compositions pharmaceutiques
MY161465A (en) Seed treatment formulations and methods of use
EP1992651A4 (fr) Derive alcool tertiaire, compose polymere et composition de photoresist
MY157716A (en) Solid dosage form of olmesartan medoxomil and amlodipine
TW200740459A (en) Pharmaceutical preparation containing an angiotensin II receptor antagonist and a calcium channel blocker
WO2008153610A3 (fr) Utilisation d'antagonistes de il-23 pour le traitement d'une infection
TW200833372A (en) Use of (meth)acrylate copolymers in delayed-release pharmaceutical forms for decreasing the influence of ethanol on the release of active compound
EP1992650A4 (fr) Derive alcool tertiaire, compose polymere et composition de photoresist
WO2009023662A3 (fr) Composition de crème solaire homogène, pulvérisable, résistante au frottement et à l'eau
WO2008008495A3 (fr) Composition formant des stéréocomplexes et dispositif médical implantable la comprenant
WO2011053003A3 (fr) Formulation à rétention gastrique et à libération prolongée contenant de la prégabaline, un oxyde de polyéthylène et un copolymère greffé pva-peg
DE502007005902D1 (de) -methyl-19-nor-20- spirox-4-en-3-one), sowie diese enthaltende pharmazeutische präparate
WO2007128478A3 (fr) Composition pharmaceutique
WO2010048389A3 (fr) Pastilles pharmaceutiques comportant de l’amidon modifié et leurs applications thérapeutiques
BRPI0720314A2 (pt) Composição, e, usos de uma composição e de um composto de triazol.
WO2008078727A1 (fr) Composition pharmaceutique à capacité de dissolution améliorée
WO2006069159A3 (fr) Compositions pharmaceutiques comprenant des composes de benzimidazole amorphe
IL197766A (en) Use of Glycopeptide Antibiotics to Prepare a Medication to Prevent Infection of Bacillus Anthracis
WO2007099555A3 (fr) Compositions pharmaceutiques contenant de l'irbésartan
WO2008156645A3 (fr) Compositions pharmaceutiques et utilisations
WO2008078726A1 (fr) Préparation solide
CL2007003517A1 (es) Compuestos derivados de quinolina sustituida; proceso de preparacion; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de una infeccion bacteriana.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07860011

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2008551105

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 1020097012660

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07860011

Country of ref document: EP

Kind code of ref document: A1